Automation Workflow for On-Demand Synthetic Control Arm Generation

This workflow directly targets the multi-million dollar cost and 6-18 month delay of recruiting real-world control arms for clinical trials. It automates the generation of privacy-preserving, statistically matched synthetic patient cohorts that preserve treatment-effect signals, enabling faster protocol finalization and go/no-go decisions. Implementation integrates with Clinical Trial Management Systems (CTMS) like Medidata or Veeva to deliver compliant, analysis-ready cohorts, reducing reliance on CROs for patient recruitment and slashing trial setup timelines.

The architecture is built for enterprise governance, embedding automated fidelity validation using propensity score metrics and KS tests to gate data release. A human review layer handles statistical outliers or complex protocol deviations, ensuring clinical plausibility. Orchestration via LangGraph or Prefect manages the multi-agent pipeline, integrating with OMOP or EHR data models. This creates a repeatable, audit-ready system that turns trial design from a data procurement bottleneck into an on-demand service, improving R&D capital efficiency.

The operational bottleneck is the manual, months-long process of designing and recruiting a real-world control arm, which delays trial starts and inflates costs. This automation workflow directly addresses that by orchestrating generative models, trial protocol logic, and validation agents to produce a ready-to-use synthetic cohort on demand. The savings come from compressing trial setup timelines by 60-80% and eliminating the direct recruitment and retention costs associated with placebo groups, while the upside is faster pipeline velocity and more agile portfolio strategy.

Implementation integrates with Clinical Trial Management Systems (CTMS) like Medidata Rave or Veeva via API connectors, ingesting protocol inclusion/exclusion criteria and historical patient data from OMOP or EHRs. The orchestration engine, built on LangGraph or Prefect, manages the agentic workflow, exception routing, and audit logging. Critical controls include automated propensity score matching validation, differential privacy checks, and a mandatory human-in-the-loop review gate by a biostatistician before the synthetic cohort is released for use in simulation or submitted to regulatory bodies.

Phase 1 establishes a standalone synthetic data engine, focusing on core generation and validation. We implement a pipeline using conditional tabular GANs or diffusion models, orchestrated via LangGraph, to produce statistically matched cohorts from aggregated, de-identified patient data. A parallel agentic workflow runs automated fidelity validation—propensity score matching, KS tests, and clinical logic checks—gating data release. This MVP delivers immediate value for internal trial design and feasibility studies, operating outside of production CTMS environments to minimize initial integration risk.

Phase 2 integrates the validated engine with the Clinical Trial Management System (CTMS), such as Medidata Rave or Oracle Clinical. We build secure API connectors that map synthetic cohort schemas to EDC case report forms, embedding protocol-specific logic for inclusion/exclusion criteria. A governance layer is added, featuring automated audit logging, re-identification risk testing, and human-in-the-loop approval gates for cohort release. This phase transitions the workflow from a design tool to an operational system capable of provisioning synthetic arms directly into active trial builds, reducing setup time from weeks to days.

This automation directly addresses the costly, slow bottleneck of recruiting real-world placebo groups. By generating on-demand synthetic control arms, sponsors can accelerate feasibility studies and trial design by months, reducing both time-to-first-patient and overall trial cost. The operational upside comes from replacing manual cohort sourcing and statistical matching with an automated, API-driven pipeline that integrates directly with Clinical Trial Management Systems (CTMS) like Medidata Rave or Veeva, ensuring seamless adoption by clinical operations teams.

Implementation requires a multi-agent architecture with strict governance checkpoints before generation and after validation. The orchestrator, built on frameworks like LangGraph, manages data ingestion from OMOP or EHR systems, triggers conditional generative models, and routes outputs through automated fidelity scoring against real-world statistical distributions. Critical controls include pre-generation protocol alignment checks, post-generation propensity score matching validation, and immutable audit logging for regulatory compliance. Rollout is sequenced, starting with sandboxed environments for biostatistics teams before integrating with production CTMS and EDC systems.